Aim:Although"lateonsethypogonadism",aconditionthatincludeslowtestosterone and symptoms, is common in men over the age of 40 years, diagnosis is not clear cut amongst non-specialists. It is the aim of this review to provide an up to date picture of how this state should be diagnosed and managed.
(iv)lateonsetHG(alsoknownastestosteronedeficiencyor"adultonset HG"). In our view, attempts to replace late onset HG with the term "functionalHG"willonlyprovidegreaterconfusionastherecanbea "functional"deficiencyinbothprimaryandsecondaryhypogonadism.
This review will focus on the diagnosis/management of primary/secondary HG in brief and late onset HG in depth to alleviate some of the prevailing confusion regarding both diagnosis and treatment.
Testosterone, the most important androgen produced by the testes, plays an integral role in men's health. 1 Androgensactatseveral sites in the sexual response system: within the CNS, peripheral nitrergicnervesandcorporacavernosa.Androgendeficiencymaybe associated with decreased libido, erectile dysfunction (ED) and insensitivity to phosphodiesterase type 5 (PDE5) inhibitor treatment. 2 
| DIAGNOSIS OF SECONDARY HYPOGONADISM (PITUITARY/ HYPOTHALAMIC DISEASE)
Anteriorpituitarypathologycanbeduetodeficiencyorhypersecretory states, with clinical symptoms and signs attributed mainly due to altered levels of hormones produced by the end organs under its regulatory control. Deficiency state could be either generalised or axis specific and often caused by non-functional pituitary adenomas, craniopharyngiomas, metastases, inflammatory diseases, haemorrhage and infarction.
Haemochromatosis (interestingly also a cause of primary HG), sarcoidosis as well as rarer infiltrative disorders can also result in pituitary damage. When hypopituitarism is diagnosed without an underlying cause beingdetecteditisclassifiedas"idiopathic"hypopituitarism.
Luteinizing hormone (LH) secreted by the anterior pituitary in response to hypothalamic gonadotrophin releasing hormone (GnRH), stimulates the interstitial (Leydig) cells to produce testosterone.Although testosterone has some direct end-organ activity, its major effects appear mediated by active metabolites following peripheral conversion into oestradiol (brain and bone) and 5α-dihydrotestosterone (in other tissues). Increased testosterone levels result in negative feedback suppressing GnRH and LH. It is important that any suspicion of pituitary or hypothalamic disorder must be referred urgently to an endocrinologist.
Thus, it is essential to be aware of the symptoms and signs of pituitary/ hypothalamic disorders, some of which are non-specific and include hypotension, weight loss, hypoglycaemia, hypothyroidism and HG.
It is important to check LH, follicle-stimulating hormone (FSH) and prolactin to differentiate secondary (pituitary/hypothalamic) from primary HG. the patient has to be matched to the individual hormone levels followed byacascadeofdynamicfunctiontestsandimaging.Ashypopituitarism is diagnosed by examining the global endocrine function and specific pituitary axes, we present a simplified investigation pathway in Figure 1 .
Suggested investigations for endocrine diseases are presented below.
| The consequences of hyperprolactinaemia
Hyperprolactinaemia is associated with ED, loss of libido and anorgasmia. 6 It is frequently accompanied by androgen deficiency since
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Message for the clinic
• The interpretation of a testosterone level found to be low on a sample taken at 09.00, requires a serum prolactin, LH and FSH measurement in order to rule out secondary hypogonadism.Also,sexhormonebindingglobulin(SHBG) measurement may help.
• It is important that multiple medical disciplines are conversant with the management of male 'late onset hypogonadism (HG)' due to its high prevalence and diverse presenting symptoms. Decisions have to be taken regarding testosterone replacement treatment based on the evidence base.
• Anunderstandingoflongitudinalstudiesofmenwithlate onset hypogonadism following TRT across primary and secondary care has the potential to yield significant morbidity and mortality benefits for our patients.
elevated prolactin levels suppress LH production leading to hypogonadism. Hyperprolactinaemia should be excluded by checking prolactin concentration in all men with diminished sexual desire. Moderate elevation of prolactin levels (<1000 mU/L) is unlikely to cause ED 7 although it may affect libido and orgasm. 8 Hyperprolactinaemia may result from the following:
• Medical and physical stress
• Drugs (notably neuroleptics and anti-emetics)
• Prolactin-secreting pituitary tumour
• Chronic renal failure Amisdiagnosisofhyperprolactinaemiacanbeduetothepresence ofmacroprolactinor"big-big"prolactin.Thisisaheterogenouscomplex of prolactin and immunoglobulin and is the cause of apparent hyperprolactaemia in about 20% of cases. 9 Macroprolactin is detected and contributes to total prolactin measured by most commercial immunoassays, and its presence should be considered in all cases of mild to moderate hyperprolactinaemia. Macroprolactinaemia is diagnosed by re-assaying prolactin following precipitation with polyethylene glycol and most clinical laboratories have protocols in place to check for this when prolactin levels are above the method dependent cut off (approximately 700-1000 mU/L). 9 To avoid unnecessary investigations, baseline prolactin levels should be measured before initiating certain long-term treatments (eg, antipsychotics). Patients with persistent and unexplained hyperprolactinaemia should be referred to an endocrinologist.
| DIAGNOSIS OF PRIMARY HYPOGONADISM
This is also known as primary testicular failure and common causes include the following:
• Klinefelter's Syndrome: the extra X chromosome results in abnormal development of the testicles leading to underproduction of testosterone.
• Undescended testicles: one or both of the testes may not descend at birth, although often correcting itself within the first few years of life without intervention. If the testes remain undescended reduced secretion of testosterone can manifest.
• Mumps orchitis: in the event of infection during adolescence or adulthood, long-term testicular damage may be evident with decreased testosterone production.
• Hemochromatosis: this can lead to both primary and secondary HG.
• Testicular trauma
• Chemotherapy or radiation therapy: this can interfere with both testosterone and sperm production and although the effects of both treatments are often short-term, permanent infertility can manifest.
| CLINICAL ASSESSMENT OF HYPOGONADISM
The presence of sexual symptoms (eg, ED, loss of libido) and generalised symptoms of HG, such as decrease in beard or body hair growth, decrease in muscle mass, gynaecomastia, osteoporosis must be ascertained on history taking. Lower testosterone levels are more likely to be associated with more clinical features of HG.
Physical examination, assessment of body mass index, the waist-hip ratio (or sagittal abdominal diameter), body hair, male pattern hair loss, presence of gynaecomastia and testicular size (measured with an orchidometer or ultrasound) and a structural examination of the penis as well as a digital rectal examination of the prostate should beincludedintheassessment.Asdescribedabove,intheeventof HG, secondary (pituitary-dependent) and primary causes need to be excluded. 
| DIAGNOSIS OF LATE ONSET HYPOGONADISM
Late onset HG is defined as a combination of sexual symptoms and serum total testosterone levels <12 nmol/L. 10 Studies have shown this age-related male HG to affect metabolic prognostic parameters of ill health in type 2 diabetes (T2DM) and morbidity/mortality risk in adult men (eg, CVD and all-cause mortality). Lower testosterone levels appear to correlate with more severe ED. 11 The validated self- overall satisfaction. 12 These domains appear affected at varying testosterone levels: loss of libido, depression in non-obese men and decreased erectile function are more frequent at total testosterone levels <15 nmol/L, <10 nmol/L and <8 nmol/L, respectively.
13
International guidance documents [14] [15] [16] 
| CAG repeats and the androgen receptor
The polymorphic number of CAG repeats within the androgen receptor gene is inversely associated with the transcriptional activity of target genes. 17 This polymorphism might thus influence testosterone effects on body fat content and serum concentrations of leptin and insulin. The direct and indirect role of androgens within the metabolic syndrome should become clearer if this genetically determined effector is taken into account. DeterminationofthenumberofCAGrepeatsmay come to be important in planning treatment for hypogonadal men, due to possible insensitivity to testosterone replacement therapy (TRT).
| Effect of other comorbidities on testosterone levels
Testosterone levels decline with age, but only between 6% and 12% of men have been described as developing late onset HG. [18] [19] [20] There are a large number of comorbid conditions which have be associated with low serum testosterone, 21 including heart failure, vascular disease, osteoporosis, dyslipidaemia, T2DM, metabolic syndrome, obesity and depression.
19,22,23
Serum testosterone levels differ by ethnic group. 24 The EMAS study 20 found that low testosterone levels were related to obesity and the metabolic syndrome (that increase with age), not just age alone, although sex hormone binding globulin (SHBG) levels increase with age with consequent decrease in free testosterone levels.
25
A total testosterone level <8 nmol/L has been proposed as a putative risk stratifier in the risk assesment for T2DM, CVD and all-cause mortality. 26 Patients with late onset HG should be considered for TRT and their symptoms monitored to assess benefit. There is a probable association between low vitamin D levels and the metabolic syndrome, including its classifying and associated factors, CVD and mortality. 27 However, the precise nature of this relationship in subgroups (eg, gender, age groups, ethnicity, etc.) is unclear. An association of secondary and compensated HG with vitamin D deficiency has also been reported. 28 Thus, far from being a benign consequence of ageing, HG has important and potentially harmful metabolic consequences including significantly increased CVD risk. 2, 29 In men with T2DM, higher SHBG and lower free testosterone levels have been strongly associated with increased mortality. 25 The link between late onset HG, ED and CVD/ mortality is clear, be estimated using online calculators (see section on free testosterone below). We recommend that both measurement of total serum testosterone and provision of calculated free testosterone should be available to the clinician, particularly when there is uncertainty in the diagnosis/management.
Circadian variation in testosterone release is the seen with peak adult testosterone levels occurring in the early morning around 09:00 am, while the lowest values (up to 60% lower) are found in the evening. 38 Thus, samples for testosterone assay should be drawn between 08:00 and 11:00 am, since there is a degree of diurnal variation in the circulating testosterone level.
There is significant variation in laboratory reference ranges quoted for total testosterone across the UK, with some laboratories applying age-related reference ranges. Ranges are often historical or based on those derived by the assay manufacturers (that need to be reviewed with any change in laboratory analytical equipment). Male testosterone levels decline with age 39 gradually decreasing with each decade after the age of 40 years, leading to late onset HG. Taking the mean testosterone at age 40 years as 100%, the expected relative levels are given in Table 1 .
In older males, these levels can be used as a guide to when the testos- Ideally, if the circulating total testosterone level is low on first measurement (12 nmol/L or less), the test should be repeated after 2 weeks as testosterone is released in a pulsatile manner and the value obtained from a single test may be misleading. It is important to ensure that the sample was definitely taken in the morning and in the event of timing uncertainty, a further repeat on 9 am sample would be necessary. Moreover, serum testosterone levels in men should be ideally checked in the fasting state on a morning sample, but non-fasting levels are acceptable. 15, 40 There is some difference across the literature 16, 41 in relation to the cut points in terms of total and free testosterone and how they relate to the syndromal definition of HG. However, our view is that, in general, hypogonadal men with a total serum testosterone thatisconsistently≤12nmol/Lwithsymptomsmightbenefitfrom a trial of TRT according to current guidelines. 14 
| Free testosterone
Accuratemeasurementoffreetestosteroneistechnicallydifficultto achieve and basic calculations using total testosterone/SHBG (eg, free androgen index) have been discredited as assessments of free testos- Appversionalsoavailable("TCalc").
In practice, in older men with suspected HG (presenting with ED) with a low or borderline-low total testosterone level, SHBG measurement may be considered at the initial visit to reduce number of visits and prevent delays to treatment. In men with a total testosterone >12 nmol/L and symptoms, an estimated circulating free testosterone <0.225 nmol/L (<225 pmol/L) suggests the patient might benefit from a trial of TRT for hypogonadism. 14, 15 Here, the estimated free testosterone potentially helps the decision to give TRT.
| Sex hormone binding globulin
Factors that are known to decrease SHBG concentration include androgens (including anabolic steroid use), obesity, hyperinsulinism, metabolic syndrome, T2DM, hypothyroidism, glucocorticoids and atorvastatin treatment. SHBG levels are known to increase with ageing, smoking, liver cirrhosis, HIV, thyrotoxicosis and rosiglitazone treatment. 44 
| INITIAL INVESTIGATIONS IN MEN PRESENTING WITH HYPOGONADISM
Initial investigations should assess common contributing factors, as well as low serum testosterone levels, which may give rise to male HG symptoms and reduce fertility/libido. 
| FURTHER ASSESSMENT OR REFERRAL ACCORDING TO CIRCULATING TESTOSTERONE LEVEL

| Total testosterone level <8 nmol/L, and/or estimated free testosterone <0.225 nmol/L (<225 pmol/L), and unequivocally abnormal LH/FSH
It is recommended 19, 45 that all patients with results which strongly suggest secondary or primary HG should be referred to a specialist to elucidate the cause, assess the potential associated pituitary or testicular pathology and establish the appropriate replacement therapy.
Long-term follow-up and monitoring of treatment may be carried out in primary care depending on the underlying pathology and treatment.
In borderline cases where the pattern is unclear, it is recommended that the tests are repeated. Patients with total testosterone <8 nmol/L and/or estimated free testosterone <0.225 nmol/L (<225 pmol/L) on two consecutive occasions require investigation of the cause of their HG.
| Total testosterone 8-12 nmol/L, with variable estimated free testosterone, LH and FSH results:
Many of these men will be classified as having late onset HG. Most patients with a total testosterone between 8 and 12 nmol/L will not be hypogonadal if asymptomatic, and will not require further investigation and treatment. Patients experiencing symptoms of HG require further assessment, with TRT considered if not contraindicated. It is important to confirm symptomatic benefit with adequate testosterone replacement in these individuals. If no benefit is demonstrated despite adequate testosterone levels being attained, insensitivity states (estimation of CAG repeats) must be considered. In the case of sexual symptoms, it is essential that TRT is not discontinued prematurely.
| Total testosterone levels >12 nmol/L
Patients with two consecutive total testosterone >12 nmol/L and/ or estimated free testosterone >0.225 nmol/L (>225 pmol/L) do not warrant treatment. Re-testing after 6-12 months may be considered in some cases.
| Further laboratory testing
When assessing patients with potential late onset HG, it may be prudent to undertake some extra testing when assessing these patients. This could include glucose/HbA1c, liver function tests, urea and electrolytes, Full Blood Count (FBC) and serum prostate specific antigen (PSA) prior to consideringTRT. Patient counseling is recommendedtoexplaintheimplicationsofmeasuringserumPSA,including a discussion on the benefits and drawbacks of the test. 46 Two prostate pathologies are associated with testosterone levels: benign prostatic hyperplasia and prostate cancer. These pathologies tend to occur after 40 years of age just when testosterone levels are seen to decrease. The evidence is that there appears to be no increased risk of prostate cancer following TRT. 16 Prostate cancer is a dihydrotestosterone responsive tumour and much of the therapy targets testosterone/dihydrotestosterone production.
Examples of anti-androgen therapy include: (i) goserelin, a GnRH analogue to suppress gonadotrophins, producing a hypopituitary hypogonadal picture, (ii) cyproterone acetate, an androgen receptor antagonist having little effect on gonadotrophin/testosterone levels, (iii) Finasteride, a 5α-reductase inhibitor blocking the activation of testosterone to 5α-dihydrotestosterone.
| TREATMENT OF LATE ONSET HYPOGONADISM
Despite mounting evidence that TRT is associated with benefit in late onset HG, practice has been slow to take this into account.
The cause of HG should always be sought before TRT is initiated (PDE5 inhibitors can be used if ED is seen, although it is well recognised that some patients on these agents may only benefit optimally when testosterone levels are normalised). Interestingly, in a metaanalysis by Corona et al., 47 nearly all studies included comprised of populations of men without "classic" hypogonadism; the resulting positive results reported in those studies indicated that symptomatic testosterone-deficient men benefited from TRT regardless of the underlying aetiology. These results provide evidence that directly contradict recommendations to limit the use of TRT only to men with classic hypogonadism. 47 PriortoTRT,allpatientsmusthavebaselinehaematocritandPSA measured. Following TRT, a small proportion of men can demonstrate aggression and mood change, hence, it is our practice to initially offer testosterone gel in view of a more rapid response related to shorter half-life followed by a discussion with the patient regarding conversion to a longer acting injectable preparation.
TRT is usually administered by topical gel, injection, patches or implants (but patches are no longer available in Europe). Oral testosterone replacement is not recommended due to a high first pass hepatic metabolism of testosterone. A range of well-tolerated testosterone formulations are available, including:
• Transdermal gel (Testogel ® , Testim ® , Tostran ® )
• Long-acting testosterone undecanoate injection (every 10-12 weeks) (Nebido ® )
• Traditionaldepotinjection(3-weekly)(Sustanon ® , etc.)
• Implanted pellets (the oldest form of testosterone replacement,
firstusedin1938andnowrarely)
Hypogonadal men restored to the eugonadal state with testosterone replacement may experience improvements in:
• sexual and erectile function Following TRT, improvement in sexual desire is relatively rapid appearing after 3weeks of treatment, and reaching a plateau at 6 weeks 36, 50 . However, changes in erectile function and ejaculation may require up to 6 months of TRT to show significant improvement. by some guidelines.
36,50
The response to treatment should be assessed at 3, 6, 9 and 12 months after the onset of treatment, and thereafter annually, including assessment of serum testosterone, haematocrit levels (as part of a FBC profile),serumPSAandothermetabolicparameters(eg,lipidprofile).
16
Bone mineral density (BMD) should be monitored only in men
whereitwasabnormalbeforeinitiationofTRT.Anincreaseinlumbar spine BMD may already be detectable after 6 months of TRT and may continue for 3 more years. 52 Testosterone stimulates erythropoiesis via several mechanisms involving increased erythropoietin secretion and promoting differentiation of erythroid progenitor cells of the bone marrow. Increases in haematocrit to the supra-physiological ranges is the most frequent side effect of TRT and may be theoretically associated with hyper-viscosity and thrombosis and be a risk factor for cerebral ischaemia. Consequently, the effect of erythropoiesis may becomeevidentat3monthsandpeaksat12months. 52 When uncertain of the implications, we recommend a discussion with a haematologist as opposed to a panic driven discontinuation of treatment. It is our local practice, we have received reassurance from our colleagues in haematology regarding haematocrit levels up to 0.56.
FollowingTRT,thereisamarginalincreaseinPSAandprostatevol-
ume, plateauing at 12 months. there appears to be no increased risk of prostate cancer following TRT. 16 
| CONCLUSION
The focus of this review is low testosterone levels associated with HG, a common phenomenon in middle aged and older men, i.e. late onset HG. Clinical training emphasises the importance of approaching most chronic pathologies from the clinical presentation and working backwards towards the aetiology before deciding on the management.
With many testosterone based myths present in healthcare circles, we felt that it was best to approach the topic from the hormone, central to much of HG.
The requesting of testosterone should be clinically driven.
Testosterone should be checked in the fasted state and when low should be repeated. Free testosterone must be calculated in certain circumstances. When low testosterone levels have been confirmed, the underlying aetiology will have to be determined: primary, secondary and late onset HG. Primary and secondary HG requires referral to appropriate specialists.
It is important that multiple medical disciplines understand the management of male late onset HG due to high prevalence and diverse presenting symptoms. Decisions have to be taken regarding TRT based on evidence which has been accumulating. We have presented some of this evidence and details of TRT and post-treatment clinical and laboratory monitoring.An understanding of longitudinal studies of men with late onset HG following TRT across primary and secondary care has the potential to yield significant morbidity and mortality benefits.
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